- GlobeNewswire•7 days agoTonix Pharmaceuticals Presented Details of Newly Expanded Product Development Pipeline at 9th Annual Biotech Showcase Conference
Development Programs Include Phase 3- Ready Breakthrough Therapy TNX-102 SL, Designed for Bedtime Dosing for PTSD, IND Drug Candidate TNX-601 Designed for Daytime Dosing for PTSD, and Smallpox Preventing ...
- Zacks Small Cap Research•13 days ago
On December 19, 2016, Tonix Pharmaceuticals Holding Corp. (TNXP) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to TNX-102 SL for the treatment of posttraumatic stress disorder (PTSD). BTD was introduced in 2012 with the Food and Drug Administration Safety and Innovation Act (FDASIA).
- GlobeNewswire•14 days agoTonix Pharmaceuticals to Present Breakthrough Therapy Designated-PTSD Program and Corporate Update at 9th Annual Biotech Showcase Conference
TNX-102 SL, a Phase 3 Drug candidate, recently granted Breakthrough Therapy designation by the FDA. Pivotal study in military-related PTSD to begin this quarter. NEW YORK, Jan. 03, 2017-- Tonix Pharmaceuticals ...
TNXP : Summary for Tonix Pharmaceuticals Holding C - Yahoo Finance
Tonix Pharmaceuticals Holding Corp. (TNXP)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
|Bid||0.53 x 200|
|Ask||0.54 x 2400|
|Day's Range||0.51 - 0.55|
|52 Week Range||0.35 - 5.40|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-0.25|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|